Mena[superscript calc], a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer
Author(s)
Forse, Catherine L.; Agarwal, Seema; Pinnaduwage, Dushanthi; Gertler, Frank; Condeelis, John S.; Lin, Juan; Xue, Xiaonan; Johung, Kimberly; Mulligan, Anna Marie; Rohan, Thomas E.; Bull, Shelley B.; Forse, Catherine L.; Condeelis, John S.; Mulligan, Anna Marie; Rohan, Thomas E.; Bull, Shelley B.; Andrulis, Irene L.; ... Show more Show less
Download12885_2015_Article_1468.pdf (768.0Kb)
OPEN_ACCESS_POLICY
Open Access Policy
Creative Commons Attribution-Noncommercial-Share Alike
Metadata
Show full item recordAbstract
Background
Mena[superscript calc] is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Mena[superscript calc] and risk of death from breast cancer. Our goal was to determine if Mena[superscript calc] could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer.
Methods
Analysis of the association of Mena[superscript calc] with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Mena[superscript calc] with risk of death after adjustment for HER2 status and clinicopathological tumor features.
Results
High Mena[superscript calc] was associated with increased risk of death from any cause (P = 0.0199, HR (CI) = 2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Mena[superscript calc] cohort which did not receive hormone or chemotherapy (n = 142) (P = 0.0052, HR (CI) = 3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Mena[superscript calc] in the HER2, basal and luminal molecular subtypes.
Conclusions
Mena[superscript calc] may serve as an independent prognostic biomarker for the ANN breast cancer patient population.
Date issued
2015-06Department
Massachusetts Institute of Technology. Department of Biology; Koch Institute for Integrative Cancer Research at MITJournal
BMC Cancer
Publisher
BioMed Central
Citation
Forse, Catherine L., Seema Agarwal, Dushanthi Pinnaduwage, Frank Gertler, John S. Condeelis, Juan Lin, Xiaonan Xue, et al. “Mena[superscript calc], a Quantitative Method of Metastasis Assessment, as a Prognostic Marker for Axillary Node-Negative Breast Cancer.” BMC Cancer 15, no. 1 (December 2015).
Version: Final published version
ISSN
1471-2407